Welcome to
Gilead Medical Information

This site is an online medical resource that provides access to scientific information about Gilead products and related information. The information provided is not intended to be and should not be understood to provide medical advice.

Choose an option that describes you:

By clicking “I’m a US healthcare professional”, you’re acknowledging that you’re a healthcare professional practicing in the US. This site is an educational resource for US healthcare professionals and may include products or uses that have not been approved by the US Food and Drug Administration.

ESMO GI

ESMO GI
July 01-04, 2026
Munich, Germany

European Society for Medical Oncology Gastrointestinal Cancers .

Explore more information for Gilead Oncology therapies

Material Type

Oral Presentation

Filter by Keyword(s)

Results (1)

STAR-221: A phase 3 study of first-line (1L) domvanalimab (D), zimberelimab (Z), and chemotherapy (chemo) vs nivolumab (N) + chemo in advanced HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC)

Author(s): Rha SY

domvanalimab
zimberelimab
Oncology

View Oral Presentation

Welcome to Gilead Medical Information

Choose an option that describes you:

ESMO GI

Filter results with keywords such as:

STAR-221: A phase 3 study of first-line (1L) domvanalimab (D), zimberelimab (Z), and chemotherapy (chemo) vs nivolumab (N) + chemo in advanced HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC)

Chat

Medical Inquiry

Meeting Request

You are leaving this website

Welcome to
Gilead Medical Information